Patents by Inventor Mark Gelfand
Mark Gelfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11974804Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.Type: GrantFiled: July 1, 2021Date of Patent: May 7, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Denise Zarins, Hanson Gifford, III, Mark E. Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
-
Patent number: 11963718Abstract: Microwave catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a microwave transmission element to a renal artery via an intravascular path. Renal neuromodulation may be achieved via dielectric heating in the presence of microwave irradiation that modulates neural fibers that contribute to renal function or alters vascular structures that feed or perfuse the neural fibers.Type: GrantFiled: May 19, 2021Date of Patent: April 23, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Karun D. Naga, Roman Turovskiy, Denise Zarins, Mark Gelfand, Arye Rosen
-
Patent number: 11963714Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.Type: GrantFiled: June 14, 2021Date of Patent: April 23, 2024Assignee: Medtronic Ireland Manufacturing Unlimited CompanyInventors: Mark E. Deem, Hanson S. Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
-
Publication number: 20240115310Abstract: A method to treat a human patient including: advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient to a target region in the lung, injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume from the distal portion of the catheter into the target region; delivering energy from the distal portion into the hypertonic saline solution in the target region, wherein the energy heats the hypertonic saline solution in the target region; ablating the target region with the heated conductive hypertonic saline solution, sensing electric impedance or electric conductivity of the target region during the delivery of the energy, and controlling the rate or a bolus of the hypertonic saline solution injected into the target region based on the electric impedance or the electric conductivity.Type: ApplicationFiled: October 16, 2023Publication date: April 11, 2024Inventors: Dorin Panescu, Shashank Raina, Simplicio Velilla, Mark Gelfand, Mark Leung
-
Patent number: 11925409Abstract: An ablation catheter configured to ablate tissue in a lung of a patient including: a flexible shaft that advances endobronchially into an airway of the lung and has an outer diameter of 2.0 mm or less; an ablation electrode attached to a distal portion of the flexible shaft and to deliver radiofrequency (RF) electrical current to the tissue and conductively connectable to an RF electrical energy source external to the patient; wherein an outer diameter of an assembly of the flexible shaft and the ablation electrode is no greater than 2.0 mm; a liquid outlet on the distal portion and configured to be in fluid communication with a source of hypertonic saline solution; and a first occluder attached to the flexible shaft proximal to the ablation electrode and proximal to the liquid outlet, wherein the first occluder is configured to expand to occlude the airway.Type: GrantFiled: November 3, 2020Date of Patent: March 12, 2024Assignee: ZIDAN MEDICAL INC.Inventors: Dorin Panescu, Shashank Raina, Mark Gelfand, Mark Leung, Simplicio Velilla
-
Publication number: 20240033517Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.Type: ApplicationFiled: August 9, 2023Publication date: February 1, 2024Inventors: Howard Levin, Mark Gelfand
-
Patent number: 11883659Abstract: A means for treating breathing disorders by stimulating respiratory muscles or nerves to entrain respiratory systems while leaving respiratory drive intact. Embodiments of the invention employ frequency analysis to determine if appropriate stimulation energy is being applied.Type: GrantFiled: June 17, 2021Date of Patent: January 30, 2024Assignee: ZOLL RESPICARDIA, INC.Inventors: Mark Gelfand, Kristofer J. James, Randy W. Westlund, Antonios Panteleon, Todd P. Goblish, Mark C. Lynn
-
Publication number: 20240024682Abstract: Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.Type: ApplicationFiled: February 21, 2023Publication date: January 25, 2024Inventors: Mark GELFAND, Tamara Colette BAYNHAM, Howard LEVIN
-
Patent number: 11864826Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.Type: GrantFiled: February 9, 2021Date of Patent: January 9, 2024Assignee: Axon Therapies, Inc.Inventors: Howard Levin, Mark Gelfand
-
Publication number: 20230414871Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.Type: ApplicationFiled: May 23, 2023Publication date: December 28, 2023Inventors: Andrew V. Halpert, Mark Tauscher, Mark Gelfand, Howard Levin
-
Patent number: 11844569Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: August 15, 2023Date of Patent: December 19, 2023Assignee: Axon Therapies, Inc.Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung
-
Publication number: 20230380901Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: August 15, 2023Publication date: November 30, 2023Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
-
Publication number: 20230380896Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: ApplicationFiled: August 7, 2023Publication date: November 30, 2023Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG
-
Publication number: 20230355300Abstract: A system for treatment of a target region of lung tissue including: a flow regulator configured to be interposed between a conductive fluid source and a conductive fluid outlet positionable at or in proximity of the target region of lung tissue, the flow regulator being further configured for controlling a flow rate or a bolus quantity of conductive fluid coming from the fluid source and delivered to the conductive fluid outlet; and a controller communicatively connectable with said flow regulator and with at least one sensor, with the at least one sensor being configured for detecting values taken by at least one control parameter representative of a physical property, wherein the physical property is one of temperature (T), pressure (p), electric impedance (Z), or electric conductivity (C) of material present at or in proximity of the target region of lung tissue.Type: ApplicationFiled: September 27, 2021Publication date: November 9, 2023Inventors: Dorin PANESCU, Shashank RAINA, Simplicio Aguilar VELILLA, Mark GELFAND, Mark LEUNG
-
Publication number: 20230347146Abstract: A system for treating disordered breathing of a human being includes an implantable transvenous stimulation lead having at least one stimulation electrode and a sensor configured to detect activity level of the human being. The system includes an energy source, a pulse generator and circuitry, the circuitry operative to receive a signal indicative of the activity level of the human being from the sensor, wherein the circuitry is configured to cause the energy source and the pulse generator to deliver spaced apart stimulation signals to the at least one stimulation electrode while the activity level of the human being is sufficiently low to be indicative of sleep. Spaced apart stimulation pulses from the electrode are configured to extend a duration of a time of at least one breath being defined as the time from an onset of inhalation to the onset of inhalation of a successive breath.Type: ApplicationFiled: July 11, 2023Publication date: November 2, 2023Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert, Antonios Panteleon
-
Patent number: 11801092Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.Type: GrantFiled: October 26, 2021Date of Patent: October 31, 2023Assignee: Axon Therapies, Inc.Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
-
Publication number: 20230301711Abstract: A system for treatment of a target region of lung tissue including: a flow regulator configured to be interposed between a conductive fluid source and a conductive fluid outlet at a distal region of a catheter positioned in the target region and the conductive fluid outlet is positionable at or in proximity of the target region of lung tissue, wherein the flow regulator being further configured to control a flow rate or a bolus quantity of the conductive fluid coming from the fluid source and delivered through the conductive fluid outlet to the target region; an ablation electrode mounted to the distal region of the catheter; a controller configured to control the flow regulator, and configured to control power delivered from an ablation energy source to the ablation electrode, wherein the controller is configured to: receive one or more of the values of the control parameter; control the delivery of power from the ablation energy source to the ablation electrode; while the power is delivered to the ablationType: ApplicationFiled: August 16, 2021Publication date: September 28, 2023Inventors: Shashank RAINA, Shivkumar SABESAN, Mark GELFAND, Miriam TAIMISTO
-
Patent number: 11759639Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.Type: GrantFiled: June 29, 2021Date of Patent: September 19, 2023Assignee: BackBeat Medical, LLCInventors: Howard Levin, Mark Gelfand
-
Patent number: 11751939Abstract: Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: January 28, 2019Date of Patent: September 12, 2023Assignee: Axon Therapies, Inc.Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung
-
Patent number: 11712296Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.Type: GrantFiled: February 18, 2020Date of Patent: August 1, 2023Assignee: Axon Therapies, Inc.Inventors: Dorin Panescu, Andrew Wu, Zoar Jacob Engelman, Mark Gelfand, Mark S. Leung, Howard Levin